Last reviewed · How we verify
Carvedilol CR + Lisinopril
Carvedilol CR (a non-selective beta-blocker with alpha-blocking activity) combined with Lisinopril (an ACE inhibitor) reduces blood pressure and cardiac workload through dual pathway inhibition.
Carvedilol CR (a non-selective beta-blocker with alpha-blocking activity) combined with Lisinopril (an ACE inhibitor) reduces blood pressure and cardiac workload through dual pathway inhibition. Used for Heart failure with reduced ejection fraction, Hypertension, Post-myocardial infarction management.
At a glance
| Generic name | Carvedilol CR + Lisinopril |
|---|---|
| Also known as | Prinivil, Coreg |
| Sponsor | St. Paul Heart Clinic |
| Drug class | Beta-blocker + ACE inhibitor combination |
| Target | Beta-adrenergic receptors (β1, β2, α1) and Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Carvedilol blocks beta-1, beta-2, and alpha-1 adrenergic receptors, reducing heart rate, contractility, and peripheral vascular resistance. Lisinopril inhibits angiotensin-converting enzyme, preventing formation of angiotensin II and reducing vasoconstriction and aldosterone secretion. Together, they provide complementary hemodynamic benefits for heart failure and hypertension management.
Approved indications
- Heart failure with reduced ejection fraction
- Hypertension
- Post-myocardial infarction management
Common side effects
- Dizziness
- Fatigue
- Hypotension
- Bradycardia
- Cough
- Hyperkalemia
Key clinical trials
- Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI. (PHASE4)
- Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril (PHASE3)
- Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab (PHASE2)
- Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease (PHASE1, PHASE2)
- Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives (PHASE1)
- Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure (PHASE3)
- The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial (PHASE3)
- The CLEVER Study - Coreg And Left Ventricular Mass Regression (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carvedilol CR + Lisinopril CI brief — competitive landscape report
- Carvedilol CR + Lisinopril updates RSS · CI watch RSS
- St. Paul Heart Clinic portfolio CI